Literature DB >> 29910163

Prostatic Artery Embolization with 250-μm Spherical Polyzene-Coated Hydrogel Microspheres for Lower Urinary Tract Symptoms with Follow-up MR Imaging.

Tobias Franiel1, René Aschenbach2, Sarah Trupp2, Thomas Lehmann3, Friedrich-Carl von Rundstedt4, Marc-Oliver Grimm4, Ulf Teichgräber2.   

Abstract

PURPOSE: To evaluate clinical outcomes and possible MR imaging predictors of clinical success after prostatic artery embolization (PAE) with 250-μm hydrogel particles.
MATERIALS AND METHODS: During a span of 1.5 years, 30 patients with moderate to severe lower urinary tract symptoms were included in a prospective, nonrandomized study. Embolization of at least one prostatic artery was considered as technical success. International Prostate Symptom Score (IPSS), quality of life (QOL), peak urinary flow rate (Qmax), residual urine volume, prostate volume, prostate-specific antigen level, and International Index of Erectile Function (IIEF) were recorded at baseline and at 1, 3, and 6 months after PAE. Multiparametric MR imaging was performed before PAE (n = 25) and 1 day (n = 25), 1 month (n = 7), 3 months (n = 7), and 6 months (n = 22) after intervention. A Wilcoxon-Mann-Whitney test was used to assess changes over time, and Spearman rank-correlation coefficient was used for outcome prediction.
RESULTS: PAE was technically successful in 90% of patients (n = 27). Clinical success (IPSS < 18 with decrease > 25% and QOL score < 4 with decrease ≥ 1 or Qmax ≥ 15 mL/s and increase of ≥ 3.0 mL/s) rates were 59% (16 of 27), 63% (17 of 27), and 74% (20 of 27) after 1, 3, and 6 mo, respectively. IIEF scores did not differ significantly during follow-up. The following adverse events occurred after PAE: urethral burning (5 of 27), fever (2 of 27), and urethral bleeding, rectal bleeding, cystitis, and penile burning sensation (1 of 27 each). No statistical correlations between initial multiparametric MR imaging changes and clinical parameters after 6 months were found (P values from .14 to .98).
CONCLUSIONS: PAE with 250-μm hydrogel microspheres led to good clinical success after 6 months with a low complication rate. Significant MR imaging predictors of clinical success were not identified.
Copyright © 2018 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29910163     DOI: 10.1016/j.jvir.2018.03.014

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  5 in total

1.  The value of contrast-enhanced ultrasonography in detection of prostatic infarction after prostatic artery embolization for the treatment of symptomatic benign prostatic hyperplasia.

Authors:  Hippocrates Moschouris; Konstantinos Stamatiou; Katerina Malagari; Kyriaki Marmaridou; Konstantinos Kladis-Kalentzis; Michail Kiltenis; Nikolaos Papadogeorgopoulos; Aikaterini Tsavari; Kassiani Manoloudaki
Journal:  Diagn Interv Radiol       Date:  2019-03       Impact factor: 2.630

2.  Prostatic artery embolization: magnetic resonance image (MRI) findings in the early detection of prostate infarction in a canine spontaneous benign prostatic hyperplasia model.

Authors:  Vanesa Lucas-Cava; Francisco Miguel Sánchez-Margallo; Virginio García-Martínez; Carmen López-Sánchez; Claudia Báez-Díaz; Luis Dávila-Gómez; Juan Rafael Lima-Rodríguez; Fei Sun
Journal:  Transl Androl Urol       Date:  2021-02

Review 3.  Clinical predictive factors in prostatic artery embolization for symptomatic benign prostatic hyperplasia: a comprehensive review.

Authors:  Fei Sun; Vanesa Lucas-Cava; Francisco Miguel Sánchez-Margallo
Journal:  Transl Androl Urol       Date:  2020-08

Review 4.  Modern imaging and image-guided treatments of the prostate gland: MR and ablation for cancer and prostatic artery embolization for benign prostatic hyperplasia.

Authors:  João Lopes Dias; Tiago Bilhim
Journal:  BJR Open       Date:  2019-08-14

Review 5.  New Ultra-minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia: A Systematic Review and Analysis of Comparative Outcomes.

Authors:  Enrico Checcucci; Alessandro Veccia; Sabrina De Cillis; Federico Piramide; Gabriele Volpi; Daniele Amparore; Angela Pecoraro; Alberto Piana; Stefano Granato; Paolo Verri; Michele Sica; Juliette Meziere; Beatrice Carbonaro; Stefano Piscitello; Davide Zamengo; Giovanni Cacciamani; Zhamshid Okhunov; Stefano Puliatti; Mark Taratkin; Josè Marenco; Juan Gomez Rivas; Domenico Veneziano; Umberto Carbonara; Giorgio Ivan Russo; Stefano De Luca; Matteo Manfredi; Cristian Fiori; Riccardo Autorino; Francesco Porpiglia
Journal:  Eur Urol Open Sci       Date:  2021-09-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.